NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $10.17 +0.02 (+0.20%) Closing price 04:00 PM EasternExtended Trading$10.11 -0.06 (-0.59%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About iTeos Therapeutics Stock (NASDAQ:ITOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iTeos Therapeutics alerts:Sign Up Key Stats Today's Range$10.11▼$10.2050-Day Range$8.22▼$10.3552-Week Range$4.80▼$18.13Volume1.05 million shsAverage Volume1.41 million shsMarket Capitalization$389.21 millionP/E RatioN/ADividend YieldN/APrice Target$15.64Consensus RatingHold Company Overview iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA. Read More iTeos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreITOS MarketRank™: iTeos Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 385th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingiTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about iTeos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about iTeos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.45% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 4.81%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.45% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 4.81%, indicating that investor sentiment is decreasing. News and Social Media1.7 / 5News Sentiment0.10 News SentimentiTeos Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,202,116.00 in company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Stock News HeadlinesQ2 EPS Estimate for iTeos Therapeutics Lowered by AnalystJuly 25 at 2:25 AM | americanbankingnews.comiTeos Therapeutics (NASDAQ:ITOS) Receives "Outperform" Rating from WedbushJuly 23 at 2:15 AM | americanbankingnews.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 25 at 2:00 AM | Paradigm Press (Ad)SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of ShareholdersJuly 21, 2025 | globenewswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.July 21, 2025 | prnewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)July 21, 2025 | globenewswire.comITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to ShareholdersJuly 21, 2025 | tmcnet.comiTeos Therapeutics to be acquired by Concentra BiosciencesJuly 21, 2025 | msn.comSee More Headlines ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $7.68 on January 1st, 2025. Since then, ITOS shares have increased by 32.4% and is now trading at $10.17. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its quarterly earnings results on Monday, April, 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? Top institutional investors of iTeos Therapeutics include Regency Capital Management Inc. DE (0.15%), KLP Kapitalforvaltning AS (0.14%) and CWM LLC (0.03%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Michel Detheux, Matthew Gall and David Hallal. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings4/28/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for iTeos Therapeutics$15.64 High Price Target$46.00 Low Price Target$8.00 Potential Upside/Downside+53.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.41 million Net MarginsN/A Pretax Margin-336.72% Return on Equity-21.37% Return on Assets-18.55% Debt Debt-to-Equity RatioN/A Current Ratio14.13 Quick Ratio14.13 Sales & Book Value Annual Sales$35 million Price / Sales11.12 Cash FlowN/A Price / Cash FlowN/A Book Value$16.16 per share Price / Book0.63Miscellaneous Outstanding Shares38,274,000Free Float33,490,000Market Cap$389.25 million OptionableOptionable Beta1.49 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ITOS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.